DBV Technologies

We are a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy.See our community guidelines:

[DBV Technologies @DBVTechnologies]

A proud moment for our team! We were featured on the @Nasdaq Tower for #FoodAllergyAwarenessWeek; a meaningful reminder of the families we aim to serve.

We’re dedicated to advancing pediatric #FoodAllergy care and supporting our community every step of the way.

Discover more about our mission: https://t.co/3Qb3iPfi5y #FAAW2026

[DBV Technologies @DBVTechnologies]

Our team is coming together in teal to show support for the food allergy community. Behind our work are people with lived experiences and personal connections, as parents, physicians, advocates, and individuals who understand the impact food allergies can have on everyday life.

We understand firsthand how food allergies may be unseen but should never be unnoticed. Sharing these perspectives is one way we continue to build awareness and strengthen our mission of advancing pediatric #FoodAllergy care.

Learn more about our team and commitment: https://t.co/UPFNLaZMrv

#FAAW2026

[DBV Technologies @DBVTechnologies]

May is #FoodAllergyAwarenessMonth! For millions of families, food allergy is more than a diagnosis, it is a daily reality that requires constant awareness, preparation, and care. This month, we’re highlighting the importance of education, advocacy, and continued progress in pediatric food allergy care.

At DBV Technologies, we’re proud to work alongside organizations to create a future where children and families can navigate food allergies with confidence.

Learn more from our advocacy partners: @AllergyAsthmaHQ, @AAFA_Advocacy, @FoodAllergy, FAACT and @FoodAllergyCAN.

[DBV Technologies @DBVTechnologies]

Today, we reported first quarter 2026 financial results. Read the full press release here: https://t.co/DIncEzhKWj

[DBV Technologies @DBVTechnologies]

How can a potential #FoodAllergy treatment harness the powerful immune properties of the skin?

Our VIASKIN® technology platform leverages epicutaneous immunotherapy (EPIT) to potentially desensitize patients to allergens like peanuts and milk by delivering microgram amounts of allergens through intact skin without entering the bloodstream.

Watch the video to learn more: https://t.co/MbBxm5i1bk

[DBV Technologies @DBVTechnologies]

#PeanutAllergy often starts in early childhood and can persist into adulthood. For many families, this means years of daily caution, lifestyle changes, and emotional stress.

We understand that food allergy management can feel overwhelming, and that every person’s journey is unique. That’s why we’re developing options that may allow families to take a more proactive approach to care.

As part of our commitment to the food allergy community and offering solutions to families, regardless of where they are in their journey, we plan to expand our clinical research to include infants aged 6–12 months with peanut allergy in a first-of-its-kind Phase 2 study.

In addition to clinical evidence across age groups, we believe epicutaneous immunotherapy (EPIT) has the potential to modify the trajectory of peanut allergy. Learn more about our technology and approach here: https://t.co/MbBxm5i1bk

[DBV Technologies @DBVTechnologies]

Passionate about innovation that makes an impact?

Our team is focused on bringing VIASKIN® – our investigational treatment platform designed to alleviate the burden of #FoodAllergy care – to children and families.

If you're looking to grow your career while delivering meaningful solutions that make a difference, explore our open roles across the U.S. and France: https://t.co/oKzCLvuaxu

[DBV Technologies @DBVTechnologies]

In the U.S. alone, peanut allergy affects ~400,000 children between the ages of 4–7.

A significant unmet need remains for more proactive approaches that not only reduce the frequency and severity of allergic reactions but also address existing barriers to care.

VITESSE, our Phase 3 study in peanut-allergic children aged 4–7, evaluated the VIASKIN® Peanut Patch. Recent positive topline results were announced, followed by additional data presented last month.

Subscribe to stay up to date on our latest data and presentations: https://t.co/x5ZpfvUnqy

[DBV Technologies @DBVTechnologies]

We’re pleased to report our full year 2025 financial results, reflecting
strong momentum and disciplined execution across clinical
development, regulatory progress, and financial strategy. ​

We remain on track to submit two separate BLAs in 4-7-year-olds and
1-3-year-olds, in the first half and second half of the year respectively,
progressing toward delivering on our mission to bring new
practical, treatment options to peanut allergic children and their
families ​

Read the full earnings here: https://t.co/ogyrlQMbZO

[DBV Technologies @DBVTechnologies]

We are proud to share that DBV Technologies is joining France's CAC Mid 60 and SBF 120 indices following the Euronext Paris' 2026 annual review.

This global recognition reflects our growing momentum and continued progress toward our long-term vision to advance pediatric #FoodAllergy care.

Read the full press release to learn more: https://t.co/7R9M4oKmgV

[DBV Technologies @DBVTechnologies]

#FoodAllergy management is a journey that evolves throughout childhood. At DBV, we aim to advance solutions that meet families where they are on their journey. ​

Our investigational #PeanutAllergy patch is designed to engage the immune system and build sustained tolerance that lasts over time.
​Over 1.1 million patches have been administered to more than 1,600 children ages 1 to 7 across our clinical programs.

Driven by a commitment to developing a treatment for food allergy, we continue to push progress forward with ongoing research across multiple age groups.​

Learn more about our current pediatric #PeanutAllergy safety study in toddlers aged 1-3 here: https://t.co/FxwtltnKUt

[DBV Technologies @DBVTechnologies]

At DBV, our culture is grounded in our Four Cs, the values that shape how we work and why we do what we do to advance #FoodAllergy research for children and families.

In this employee spotlight, find out which “C” resonates the most with Jennifer Meunier, our Internal Communications Project Manager, and what it means at DBV.

If our values speak to you, we invite you to explore opportunities to join our team and help move our mission forward: https://t.co/oKzCLvuaxu

#DBVTeam

[DBV Technologies @DBVTechnologies]

We’re looking forward to connecting with leaders across the healthcare landscape next week:

1️⃣The Citizens Life Sciences Conference, where we will participate in a #FiresideChat on March 10.

2️⃣ The Leerink Partners Global Healthcare Conference, where members of our leadership team will host 1-on-1 meetings.

We welcome these opportunities to connect with industry peers and the investor community to share insights on recent company progress as we continue advancing our investigational treatment option for pediatric #PeanutAllergy.

To watch a live webcast of the Fireside Chat at Citizens, register here: https://t.co/ydftmJzvfy

The presentation will also be available on the Events section of our website. Learn more: https://t.co/cDEjCQVkCz

[DBV Technologies @DBVTechnologies]

Today, we presented at the 2026 @AAAAI_org Annual Meeting!

Swipe through data highlights and expert insights and from our:

📍Oral Abstract Presentation, where David Fleischer, MD, shared additional positive results from the successful VITESSE Phase 3 study in peanut-allergic children aged 4-7 years, including clinically meaningful changes in reaction threshold.

Read our full data release to learn more: https://t.co/sjhyrUStl2 #AAAAI26

[DBV Technologies @DBVTechnologies]

Allergic reactions are unpredictable; accidental exposures can still occur despite best efforts to avoid them. For many families, avoidance alone may not be enough.

There remains a real need for proactive approaches that not only reduce the risk and severity of allergic reactions but also address the barriers to care that exists with current therapies.

In this @ContempPEDS article, Dr. Fleischer, Global Principal Investigator of our VITESSE study in children 4-7 with #PeanutAllergy, highlights an important distinction: our investigational treatment delivers microgram amounts of peanut protein through intact skin, offering families a non-invasive approach to treatment without having to ingest the allergen.

Learn more: https://t.co/4i6NTi5R7s

[DBV Technologies @DBVTechnologies]

This month, our teams across the U.S. and France came together to connect and reflect on our progress to strengthen the partnerships that help us move forward. These moments reinforce how collaboration drives our work to advance food allergy research and potential solutions for children and families.

Behind every milestone is a global team united by purpose, innovation, and an unwavering commitment to the #FoodAllergy community.

[DBV Technologies @DBVTechnologies]

We look forward to participating at the upcoming 2026 @AAAAI_org Annual Meeting, where we will share insights and results reflecting continued progress in our investigational treatment for children and toddlers with #PeanutAllergy.

Find details on our oral abstract presentation, product theater, and company booth here: https://t.co/tY9krvEPaG

#AAAAI26

[DBV Technologies @DBVTechnologies]

Valentine’s Day is just around the corner! While many parents, teachers and students look forward to sharing sweet treats on this fun holiday, classroom celebrations can create heightened risk for accidental allergen exposure.

At DBV, we understand that this can bring added stress for families and children managing #FoodAllergies. Learn how we’re working to help reduce the risk and severity of accidental exposure reactions: https://t.co/3Qb3iPfi5y

[DBV Technologies @DBVTechnologies]

More children in the U.S. are living with #PeanutAllergy than ever before, and the increasing prevalence has driven a growing need for more accessible, safe and effective treatment options.

The COMFORT Toddlers clinical trial, a supplemental safety study evaluating our investigational treatment option in toddlers aged 1-3 years with peanut allergy, is advancing research to address this critical gap in care.

Our innovative technology based on epicutaneous immunotherapy is being developed as a non-invasive, potentially disease-modifying approach to desensitization. Uniquely designed with the needs of young children in mind, it aims to re-educate the immune system and protect from accidental exposure reactions.

In our latest research spotlight, principal investigators from participating COMFORT Toddlers clinical trial sites highlight the ongoing work to offer a potential treatment option that could benefit families and allergists alike. To learn more about our ongoing trial, visit: https://t.co/eK6GxQddpx

[DBV Technologies @DBVTechnologies]

During our recent investor call, our CEO, Daniel Tassé, shared why the positive topline results from VITESSE, our Phase 3 study in peanut-allergic children aged 4–7 years, represent a pivotal moment in our work to advance #PeanutAllergy care.

The discussion focused on how these results pave a clear regulatory pathway to FDA submission in 1H26 for our investigational, non-invasive treatment designed specifically with children and families in mind.

Watch the replay here to learn more: https://t.co/MJzlULy5Do